ARLN and osteosarcoma: In addition, ALN was found to have anti-angiogenic activity through (i) suppression of VEGF-induced Rho activation in an ovarian cancer model [46], (ii) inhibition of a key enzyme, farnesyl pyrophosphate synthase, in the mevalonate pathway, thereby preventing the biosynthesis of isoprenoid compounds that are essential for the posttranslational modification of small guanosine triphosphate (GTP)-binding proteins such as Rab, Rho, and Rac [47]; and (iii) regulation of cellular level of MMP-2 expression in osteosarcoma cell lines [48].